𝔖 Bobbio Scriptorium

✦ LIBER ✦

Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer

✍ Scribed by Shitara, Kohei; Matsuo, Keitaro; Muro, Kei; Doi, Toshihiko; Ohtsu, Atsushi

Book ID: 121633909
Publisher: Springer
Year: 2013
Tongue: English
Weight: 326 KB
Volume: 17
Category: Article
ISSN: 1436-3291
DOI: 10.1007/s10120-013-0274-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Factors affecting the association betwee

Factors affecting the association between overall survival and progression-free survival in clinical trials of first-line treatment for patients with advanced non-small cell lung cancer

✍ Aboshi, Masayuki; Kaneko, Masayuki; Narukawa, Mamoru 📂 Article 📅 2014 🏛 Springer-Verlag 🌐 English ⚖ 339 KB

Surrogate endpoints for overall survival

Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data

✍ Mauguen, Audrey; Pignon, Jean-Pierre; Burdett, Sarah; Domerg, Caroline; Fisher, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 620 KB

Survival prolongation after treatment fa

Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology Group Trials JCOG9205 and JCOG9912

✍ Takashima, Atsuo; Boku, Narikazu; Kato, Ken; Nakamura, Kenichi; Mizusawa, Junki; 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 375 KB

Individual-level data on the relationshi

Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy

✍ Hisao Imai,Keita Mori,Akira Ono,Hiroaki Akamatsu,Tetsuhiko Taira… 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 213 KB

UFT and leucovorin in first-line chemoth

UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial

✍ A. Ravaud; M. Borner; J.H.M. Schellens; L. Geoffrois; B.P. Schöffski; K. Kroon; 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 99 KB

Marimastat may not improve survival over

Marimastat may not improve survival over placebo following induction therapy for small-cell lung cancer: Abstracted from: Shepherd F, Giaccone G, Seymour L et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002; 20(22): 4434–39.

✍ B Coudert 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 71 KB